Image

Role of Candidate Proteins in Capillary Leakage During Acute Circulatory Failure

Role of Candidate Proteins in Capillary Leakage During Acute Circulatory Failure

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

  • Testing the association between circulating candidate proteins and the level of vascular leakage for three distinct forms of circulatory failure: cardiogenic shock, septic shock, and post-resuscitation syndrome.
    • Describing immuno-inflammatory profiles associated with massive vascular leakage during those three forms of circulatory failure in humans

Description

Circulatory shocks are responsible for one third of intensive care unit (ICU) admissions (20,000 patients per year in France) and are associated with 40% mortality [1,2]. Vascular hyperpermeability (also called vascular leakage) is a major feature of circulatory failure. During systemic inflammatory response syndrome (SIRS), massive vascular leakage affects macro and micro-circulation, and participates in the development of multiple organ failure [1,3]. Accordingly, fluid balance (the difference between fluid input and output) correlates independently with mortality during both septic and cardiogenic shock [4-7] and controlling capillary leakage was highly beneficial in numerous animal models of circulatory failure [8-10]. However, the determinants of vascular leakage remain poorly understood in humans.

The purpose of this study is to evaluate the link between circulatory levels of several proteins and the level of vascular leakage, in three distinct types of circulatory shocks.

Eligibility

Inclusion Criteria:

  1. Informed consent from patient or a legal representative/family member/close relative. The patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow.
  2. Affiliation to social security (AME excluded)
  3. Patient with one of the circulatory failures described below:
    • septic shock
    • cardiogenic shock
    • post-resuscitation syndrome
    • Cardiogenic shock:
      • Need for a catecholamine support to maintain mean arterial pressure>65 mmHg, AND
      • Cardiac index <2 L/min/m2 or left ventricular ejection fraction (LVEF)<35%, AND
      • Lactate >2.0 mmol/l
    • Post-resuscitation syndrome:
      • Cardiac arrest (absence of spontaneous respiration, palpable heartbeat, and responsiveness to stimuli> 1 min) with a compatible electrocardiogram (asystole/pulseless electrical activity/ventricular tachycardia), AND
      • Need for a catecholamine support to maintain mean arterial pressure>65 mmHg, AND
      • Lactate >2.0 mmol/l
    • Septic shock:
      • Suspected or proven bacterial infection
      • Need for a vasopressor support to maintain mean arterial pressure>65 mmHg
      • Lactate >2.0 mmol/l
      • Cardiac index>3L/min/m2 or LVEF>40%

Exclusion Criteria:

  1. Onset of shock (catecholamine infusion) >12 hours prior to inclusion
  2. Age <18 year old
  3. Pregnancy

Study details
    Cardiogenic Shock
    Postresuscitation Disease
    Septic Shock

NCT05586282

Assistance Publique - Hôpitaux de Paris

4 September 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.